By Artem Andrianov, Ph.D., MBA|2018-03-02T13:55:33+02:00March 2, 2018|Comments Off on FDA Adopts the ICH GCP E6 (R2)
About the Author: Artem Andrianov, Ph.D., MBA
Professional in the integration of data-driven Risk-based Quality Management (RBQM) process in international clinical trials of pharmacology.
Speaker at regional and global conferences such as: DIA, Health 2.0, DGGF, etc.
18+ years of experience in data quality projects and biostatistics for the pharmaceutical industry.
Life passion: improving clinical research with RbM, driving the RBQM research to new frontiers for CROs, pharma and biotech companies.